

CONSIDERATIONS IN CLINICAL TRIALS AND PAEDIATRIC TRIALS

EXPERIMENTAL MEDICINE TRAINING INITIATIVE/BPS CLINICAL PHARMACOLOGY NATIONAL TRAINING EVENT

PROGRAMME

14:00-14:05 - WELCOME/INTROS

DR JOSEPH CHERIYAN, DR SPOORTHY KULKARNI

**14:05-14:30 - CHALLENGES OF DESIGNING PAEDIATRIC
CLINICAL TRIALS: AN INTERACTIVE SESSION**

DR JUSTIN GREEN

AstraZeneca

**14:30-15:20 - PRINCIPLES OF DRUG SAFETY TESTING: PRE
CLINICAL AND EARLY CLINICAL PHASES: INDUSTRY
PERSPECTIVE**

DR MIKAEL PERSSON

AstraZeneca

15:20-15:30 - BREAK

**15:30-16:00 - USING DEVELOPMENTAL BIOLOGY TO
UNDERSTAND DRUG ACTION AND DRUG SAFETY**

PROFESSOR NEIL VARGESSON

University of Aberdeen




18 May 2023 Contact - **01223 256653** Location - **Teams**

www.emi-training.org/meeting.asp?id=101

Scan QR code to register and book a place



**UNIVERSITY OF
CAMBRIDGE**
School of Clinical Medicine



**BRITISH
PHARMACOLOGICAL
SOCIETY**



BIOGRAPHIES

DR JUSTIN GREEN

A pharmaceutical physician with 10+ years of Pharma Industry Experience along with a CCT in Infectious Diseases. He has experience working in leadership positions within ID Research & Development, initially with a focus on Developing World Trial delivery, but more recently on Commercial assets (e.g. Vaxzevria, AZ's Covid-19 vaccine). He has a proven track record of innovation (e.g. in trial design), paediatric clinical trials, delivery and cross-asset leadership in all phases of lifecycle management. He was Interim VP for Late Phase Clinical Development during the formation of AZ's new infection unit - Vaccines & Immune Therapies.

DR MIKAEL PERSSON

He is responsible for Discovery Safety from target selection to candidate delivery, across modalities such as small molecules, antisense oligonucleotides, regenerative medicines, and modified RNA based therapies. He leads and manage a team of true drug hunting partners who design project specific safety strategies to predict, quantitatively assess, and mitigate target and chemistry related risks, and deliver holistically optimized clinical candidates.

PROF NEIL VARGESSON

His research is focused on determining the mechanisms underlying thalidomide-induced teratogenesis; identifying non-teratogenic forms of thalidomide; studying the actions of Primodos, screening drugs to identify their function/s and action/s; studying how blood vessels are involved in controlling normal and abnormal limb development; studying the role of the YAP signaling pathway in embryonic development; using the chicken embryo to produce a model of Clubfoot to understand how this common birth anomaly comes about; and understanding how birth defects come about in general.